Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-let-7b-5p ABL1 0.6 0.0014 -1.32 0 miRNAWalker2 validate -0.23 0 NA
2 hsa-miR-149-5p ABL1 2.94 0 -1.32 0 miRNAWalker2 validate -0.14 0 NA
3 hsa-miR-484 ABL1 1.82 0 -1.32 0 miRNAWalker2 validate -0.28 0 NA
4 hsa-miR-181a-5p ATM 2.3 0 -0.69 1.0E-5 miRNAWalker2 validate; miRTarBase -0.13 3.0E-5 24531888; 27150990; 21102523; 26113450; 23656790 Ataxia-telangiectasia mutation ATM was predicted as a target gene of miR-181a with bioinformatics analysis and was verified by lucifersae reporter assay; A luciferase reporter assay demonstrated that ATM was a direct target of miR-181a miR-181a mimics transfection down regulated ATM mRNA and protein expression; There was inverse correlation between miR-181a and ATM protein expression in gastric cancer and normal gastric tissues; Our study demonstrates that over-expression of miR-181a might be involved in development of gastric cancer by promoting proliferation and inhibiting apoptosis probably through directly targeting ATM miR-181a modulation may be a potential strategy for the development of miRNA-based therapy of gastric cancer;MiR 181a Promotes Proliferation of Human Acute Myeloid Leukemia Cells by Targeting ATM; Dual luciferase reporter gene assay showed that miR-181a significantly suppressed the reporter gene activity containing ATM 3'-UTR by about 56.8% P < 0.05 but it didn't suppress the reporter gene activity containing 3'-UTR ATM mutation; Western blot showed that miR-181a significantly downregulated the expression of ATM in human leukemia cells; It is also found that miR-181a was significantly increased in AML which showed a negative correlation with ATM expression; miR-181a promotes cell proliferation in AML by regulating the tumor suppressor ATM thus it plays the role as oncogene in pathogenesis of AML;Ataxia telangiectasia mutated ATM a target gene of miR-181 exhibited reduced expression in mammospheres and upon TGF-β treatment;miR 181a promotes G1/S transition and cell proliferation in pediatric acute myeloid leukemia by targeting ATM; Pediatric AML patients and healthy controls were enrolled and the expression of miR-181a and ataxia telangiectasia mutated ATM in tissues were examined using quantitative PCR; Moreover cell proliferation and cell cycle were evaluated in several cell lines HL60 NB4 and K562 by using flow cytometry after transfected with miR-181a mimics and inhibitors or ATM siRNA and control siRNA; Finally ATM as the potential target protein of miR-181a was examined; We found that miR-181a was significantly increased in pediatric AML which showed an inverse association with ATM expression; Luciferase activity of the reporter construct identified ATM as the direct molecular target of miR-181a; The results revealed novel mechanism through which miR-181a regulates G1/S transition and cell proliferation in pediatric AML by regulating the tumor suppressor ATM providing insights into the molecular mechanism in pediatric AML;We report that miR-181a and miR-181b were overexpressed in more aggressive breast cancers and their expression correlates inversely with ATM levels
5 hsa-miR-18a-5p ATM 3.79 0 -0.69 1.0E-5 miRNAWalker2 validate; miRTarBase -0.13 0 23437304; 25963391; 23857602; 23229340 MicroRNA 18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer; Through in silico search the 3'UTR of Ataxia telangiectasia mutated ATM contains a conserved miR-18a binding site; Expression of ATM was down-regulated in CRC tumors p<0.0001 and inversely correlated with miR-18a expression r = -0.4562 p<0.01; This was further confirmed by the down-regulation of ATM protein by miR-18a; As ATM is a key enzyme in DNA damage repair we evaluated the effect of miR-18a on DNA double-strand breaks; miR-18a attenuates cellular repair of DNA double-strand breaks by directly suppressing ATM a key enzyme in DNA damage repair;However the upregulation of miR-18a suppressed the level of ataxia-telangiectasia mutated and attenuated DNA double-strand break repair after irradiation which re-sensitized the cervical cancer cells to radiotherapy by promoting apoptosis;Furthermore we used antisense oligonucleotides against micro RNAs miRNA or miRNA overexpression plasmids to study the role of miR-18a and -106a on ATM expression; Furthermore we identified that ERα activates miR-18a and -106a to downregulate ATM expression; We reveal a novel mechanism involving ERα and miR-18a and -106a regulation of ATM in breast cancer;MicroRNA 18a upregulates autophagy and ataxia telangiectasia mutated gene expression in HCT116 colon cancer cells; Previous studies showed that certain microRNAs including miR-18a potentially regulate ATM in cancer cells; However the mechanisms behind the modulation of ATM by miR-18a remain to be elucidated in colon cancer cells; In the present study we explored the impact of miR-18a on the autophagy process and ATM expression in HCT116 colon cancer cells; Western blotting and luciferase assays were implemented to explore the impact of miR-18a on ATM gene expression in HCT116 cells; Moreover miR-18a overexpression led to the upregulation of ATM expression and suppression of mTORC1 activity; Results of the present study pertaining to the role of miR-18a in regulating autophagy and ATM gene expression in colon cancer cells revealed a novel function for miR-18a in a critical cellular event and on a crucial gene with significant impacts in cancer development progression treatment and in other diseases
6 hsa-miR-19b-3p ATM 2.5 0 -0.69 1.0E-5 miRNAWalker2 validate -0.17 0 NA
7 hsa-miR-92a-3p ATM 2.06 0 -0.69 1.0E-5 miRNAWalker2 validate -0.17 0 NA
8 hsa-miR-335-5p CCNA1 1.77 0 -0.8 0.29528 miRNAWalker2 validate -0.25 0.00952 NA
9 hsa-miR-23b-3p CCNB2 -0.25 0.1502 3.44 0 miRNAWalker2 validate -0.35 8.0E-5 NA
10 hsa-miR-106b-5p CCND1 2.47 0 0.08 0.84033 miRNAWalker2 validate; miRTarBase -0.19 0.01301 NA
11 hsa-miR-15b-5p CCND1 1.57 0 0.08 0.84033 miRNAWalker2 validate; miRTarBase -0.27 0.0019 NA
12 hsa-miR-195-5p CCND1 -1.45 0 0.08 0.84033 miRNAWalker2 validate; miRTarBase -0.23 0.00278 21350001; 26631043; 25823925 Raf-1 and Ccnd1 were identified as novel direct targets of miR-195 and miR-497 miR-195/497 expression levels in clinical specimens were found to be correlated inversely with malignancy of breast cancer;MiR 195 inhibits the proliferation of human cervical cancer cells by directly targeting cyclin D1; The present study was to evaluate the level of miR-195 and cyclin D1 in CC tissues and cells; We further investigated the molecular mechanisms of miR-195 and cyclin D1 in CC cell lines HeLa and SiHa; Furthermore the expression of miR-195 was inversely proportional to that of cyclin D1 mRNA or protein p = 0.013 p = 0.015 respectively; However the inhibitor of miR-195 promoted the expression of cyclin D1 and cell proliferation; In conclusion our data suggest that miR-195 may have the potential role in treatment of CC patients as well as miR-195 is a novel regulator of invasiveness and tumorigenicity in CC cells by targeting cyclin D1;MicroRNA profiling identifies MiR 195 suppresses osteosarcoma cell metastasis by targeting CCND1; Meanwhile CCND1 was identified as the target gene of miR-195 and further studied; More importantly using real-time PCR we evaluated the expression of miR-195 and CCND1 in osteosarcoma samples from 107 frozen biopsy tissues and 99 formalin- or paraformalin-fixed paraffin-embedded FFPE tissues; Results indicated lowly expressed miR-195 or highly CCND1 correlated with positive overall survival and their expression inversely related to each other; In summary our study suggests miR-195 functions as a tumor metastasis suppressor gene by down-regulating CCND1 and can be used as a potential target in the treatment of osteosarcoma
13 hsa-miR-19a-3p CCND1 3.42 0 0.08 0.84033 miRNAWalker2 validate; miRTarBase -0.13 0.03027 25985117 Moreover miR-19a might play inhibitory roles in HCC malignancy via regulating Cyclin D1 expression
14 hsa-miR-19b-1-5p CCND1 2.58 0 0.08 0.84033 miRNAWalker2 validate; miRTarBase -0.15 0.02853 NA
15 hsa-miR-338-3p CCND1 0.45 0.14458 0.08 0.84033 miRNAWalker2 validate; miRTarBase -0.15 0.02359 NA
16 hsa-miR-365a-3p CCND1 -0.04 0.85911 0.08 0.84033 miRNAWalker2 validate; miRTarBase -0.21 0.02249 NA
17 hsa-miR-374b-5p CCND1 0.07 0.72267 0.08 0.84033 miRNAWalker2 validate -0.42 0.00013 NA
18 hsa-miR-92a-3p CCND1 2.06 0 0.08 0.84033 miRNAWalker2 validate -0.19 0.02573 NA
19 hsa-let-7a-5p CCND2 0.62 3.0E-5 -2.43 0 miRNAWalker2 validate; miRTarBase; TargetScan -0.5 0.0001 20418948 MicroRNA let 7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2
20 hsa-let-7b-5p CCND2 0.6 0.0014 -2.43 0 miRNAWalker2 validate; miRTarBase -0.37 0.0002 NA
21 hsa-miR-106b-5p CCND2 2.47 0 -2.43 0 miRNAWalker2 validate; miRTarBase -0.72 0 NA
22 hsa-miR-141-3p CCND2 5.02 0 -2.43 0 TargetScan -0.34 0 NA
23 hsa-miR-15a-5p CCND2 2.35 0 -2.43 0 miRNAWalker2 validate; miRTarBase -0.56 0 NA
24 hsa-miR-16-5p CCND2 1.76 0 -2.43 0 miRNAWalker2 validate -0.62 0 NA
25 hsa-miR-17-5p CCND2 3.27 0 -2.43 0 miRNAWalker2 validate; miRTarBase; TargetScan -0.58 0 NA
26 hsa-miR-182-5p CCND2 3.54 0 -2.43 0 miRNAWalker2 validate; miRTarBase -0.42 0 NA
27 hsa-miR-19b-3p CCND2 2.5 0 -2.43 0 miRNAWalker2 validate -0.64 0 NA
28 hsa-miR-20a-5p CCND2 3.16 0 -2.43 0 miRNAWalker2 validate; miRTarBase -0.55 0 NA
29 hsa-miR-301a-3p CCND2 2.81 0 -2.43 0 miRNAWalker2 validate -0.49 0 NA
30 hsa-miR-320a CCND2 0.44 0.03902 -2.43 0 miRNAWalker2 validate -0.37 4.0E-5 NA
31 hsa-miR-324-3p CCND2 2.09 0 -2.43 0 miRNAWalker2 validate -0.57 0 NA
32 hsa-miR-335-5p CCND2 1.77 0 -2.43 0 miRNAWalker2 validate -0.2 8.0E-5 NA
33 hsa-miR-378a-3p CCND2 -0.11 0.71619 -2.43 0 miRNAWalker2 validate -0.26 2.0E-5 NA
34 hsa-miR-423-5p CCND2 0.96 0 -2.43 0 miRNAWalker2 validate -0.68 0 NA
35 hsa-miR-877-5p CCND2 2.95 0 -2.43 0 miRNAWalker2 validate -0.36 0 NA
36 hsa-miR-96-5p CCND2 4.89 0 -2.43 0 TargetScan -0.38 0 NA
37 hsa-miR-27b-3p CCND3 0.2 0.29563 0.14 0.39731 miRNAWalker2 validate -0.13 0.00231 NA
38 hsa-miR-23b-3p CDC20 -0.25 0.1502 3.89 0 miRNAWalker2 validate -0.44 1.0E-5 NA
39 hsa-miR-30a-5p CDC20 -0.88 0.00051 3.89 0 miRNAWalker2 validate -0.14 0.03688 NA
40 hsa-let-7a-5p CDC25B 0.62 3.0E-5 0.78 0.00479 miRNAWalker2 validate -0.2 0.02874 NA
41 hsa-miR-141-3p CDC25B 5.02 0 0.78 0.00479 TargetScan -0.12 0 NA
42 hsa-miR-23b-3p CDK2 -0.25 0.1502 0.94 0 miRNAWalker2 validate -0.11 0.0284 NA
43 hsa-miR-103a-3p CDK6 1.44 0 -0.77 0.06479 miRNAWalker2 validate -0.74 0 NA
44 hsa-miR-107 CDK6 1.31 0 -0.77 0.06479 miRNAWalker2 validate; miRTarBase -0.54 0 19407485; 22491216; 21264532; 19688090 Enforced expression of miR-107 in MiaPACA-2 and PANC-1 cells downregulated in vitro growth and this was associated with repression of the putative miR-107 target cyclin-dependent kinase 6 thereby providing a functional basis for the epigenetic inactivation of this miRNA in pancreatic cancer;Levels of known miR-107 targets protein kinase Cε PKCε cyclin-dependent kinase 6 CDK6 and hypoxia-inducible factor 1-β HIF1-β decreased following NP/pre-miR-107 treatment;We have identified miR-107 as a potential regulator of CDK6 expression; A bioinformatics search revealed a putative target site for miR-107 within the CDK6 3' untranslated region; Expression of miR-107 in gastric cancer cell lines was found inversely correlated with CDK6 expression; miR-107 could significantly suppress CDK6 3' UTR luciferase reporter activity and this effect was not detectable when the putative 3' UTR target site was mutated; Consistent with the results of the reporter assay ectopic expression of miR-107 reduced both mRNA and protein expression levels of CDK6 inhibited proliferation induced G1 cell cycle arrest and blocked invasion of the gastric cancer cells; Our results suggest that miR-107 may have a tumor suppressor function by directly targeting CDK6 to inhibit the proliferation and invasion activities of gastric cancer cells;Using miRNA-target prediction analyses and the array data we listed up a set of likely targets of miR-107 and miR-185 for G1 cell cycle arrest and validate a subset of them using real-time RT-PCR and immunoblotting for CDK6
45 hsa-miR-141-3p CDK6 5.02 0 -0.77 0.06479 TargetScan -0.28 0 NA
46 hsa-miR-16-5p CDK6 1.76 0 -0.77 0.06479 miRNAWalker2 validate; miRTarBase -0.21 0.02241 NA
47 hsa-miR-17-5p CDK6 3.27 0 -0.77 0.06479 TargetScan -0.17 0.00702 NA
48 hsa-miR-185-5p CDK6 2.34 0 -0.77 0.06479 miRNAWalker2 validate -0.42 0 19688090 Using miRNA-target prediction analyses and the array data we listed up a set of likely targets of miR-107 and miR-185 for G1 cell cycle arrest and validate a subset of them using real-time RT-PCR and immunoblotting for CDK6
49 hsa-miR-191-5p CDK6 2.3 0 -0.77 0.06479 miRNAWalker2 validate; miRTarBase -0.71 0 NA
50 hsa-miR-218-5p CDK6 -0.57 0.0552 -0.77 0.06479 miRNAWalker2 validate -0.15 0.02404 23996750 Ectopic expression of miR-218 in HepG2 cells resulted in suppressed cell proliferation and enhanced cell apoptosis as well as the down-regulation of Bmi-1 and CDK6 mRNA and protein expressions P<0.05; The low-expression of miR-218 is correlated with malignant clinicopathological characteristics of HCC and miR-218 may inhibit cell proliferation and promote cell apoptosis by down-regulating Bmi-1 and CDK6 in HCC
51 hsa-miR-29b-3p CDK6 1.66 0 -0.77 0.06479 miRNAWalker2 validate; miRTarBase -0.22 0.00223 23245396; 25472644; 26180082; 23591808; 27230400; 20086245 The IFN-γ-induced G1-arrest of melanoma cells involves down-regulation of CDK6 which we proved to be a direct target of miR-29 in these cells;Moreover miR-29b inhibited the expression of MCL1 and CDK6;Knockdown of NTSR1 increased the expression of miR-29b-1 and miR-129-3p which were responsible for the decreased CDK6 expression;Here we have identified the oncogene cyclin-dependent protein kinase 6 CDK6 as a direct target of miR-29b in lung cancer;MiR 29b suppresses the proliferation and migration of osteosarcoma cells by targeting CDK6; In this study we investigated the role of miR-29b as a novel regulator of CDK6 using bioinformatics methods; We demonstrated that CDK6 can be downregulated by miR-29b via binding to the 3'-UTR region in osteosarcoma cells; Furthermore we identified an inverse correlation between miR-29b and CDK6 protein levels in osteosarcoma tissues; The results revealed that miR-29b acts as a tumor suppressor of osteosarcoma by targeting CDK6 in the proliferation and migration processes;microRNA expression profile and identification of miR 29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma; Furthermore we demonstrate miR-29 inhibition of CDK6 protein and mRNA levels by direct binding to 3'-untranslated region; Inverse correlation between miR-29 and CDK6 was observed in MCL
52 hsa-miR-29c-3p CDK6 -0.01 0.971 -0.77 0.06479 miRNAWalker2 validate; miRTarBase -0.58 0 26396669 Furthermore through qPCR and Western blot assays confirmed that overexpression of miR-29c reduced CDK6 mRNA and protein levels; miR-29c could inhibit the proliferation migration and invasion of bladder cancer cells via regulating CDK6
53 hsa-miR-34a-5p CDK6 1.9 0 -0.77 0.06479 miRNAWalker2 validate; miRTarBase -0.52 0 21702042; 26104764 Molecular analyses identified Cdk6 and sirtuin SIRT-1 as being targeted by miR-34a in MI-TCC cells however inhibition of Cdk6 and SIRT-1 was not as effective as pre-miR-34a in mediating chemosensitization;The expression of microRNA 34a is inversely correlated with c MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients; We found significant inverse correlations between miR-34a and c-MET R = -0.316 P = 0.028 and CDK6 expression R = -0.4582 P = 0.004
54 hsa-miR-501-3p CDK6 1.83 0 -0.77 0.06479 TargetScan -0.41 0 NA
55 hsa-let-7f-5p CDKN1A 0.5 0.00356 -1.29 0 miRNAWalker2 validate -0.24 0.00297 NA
56 hsa-miR-106a-5p CDKN1A 2.49 0 -1.29 0 miRNAWalker2 validate; miRTarBase -0.13 0.00055 25510666 After prediction with online software we further used dual-luciferase reporter gene assay to ensure that TP53INP1 and CDKN1A might be the direct targets of miR-106a
57 hsa-miR-106b-5p CDKN1A 2.47 0 -1.29 0 miRNAWalker2 validate; miRTarBase -0.3 0 NA
58 hsa-miR-17-5p CDKN1A 3.27 0 -1.29 0 miRNAWalker2 validate; miRTarBase; TargetScan -0.17 3.0E-5 26482648; 24989082 The low expressions of miR-17 and miR-92 families can maintain cisplatin resistance through the regulation of CDKN1A and RAD21;According to PicTar and Miranda algorithms which predicted CDKN1A p21 as a putative target of miR-17 a luciferase assay was performed and revealed that miR-17 directly targets the 3'-UTR of p21 mRNA
59 hsa-miR-182-5p CDKN1A 3.54 0 -1.29 0 miRNAWalker2 validate -0.11 0.00142 NA
60 hsa-miR-20a-5p CDKN1A 3.16 0 -1.29 0 miRNAWalker2 validate; miRTarBase -0.17 7.0E-5 26012475 Using the poorly tumorigenic and TGF-β-sensitive FET cell line that expresses low miR-20a levels we first confirmed that miR-20a downmodulated CDKN1A expression both at mRNA and protein level through direct binding to its 3'-UTR; Moreover besides modulating CDKN1A miR-20a blocked TGF-β-induced transactivation of its promoter without affecting the post-receptor activation of Smad3/4 effectors directly; Finally miR-20a abrogated the TGF-β-mediated c-Myc repression a direct inhibitor of the CDKN1A promoter activation most likely by reducing the expression of specific MYC-regulating genes from the Smad/E2F-based core repressor complex
61 hsa-miR-20b-5p CDKN1A 2.08 1.0E-5 -1.29 0 miRNAWalker2 validate; miRTarBase -0.11 7.0E-5 NA
62 hsa-miR-28-5p CDKN1A 0.23 0.07429 -1.29 0 miRNAWalker2 validate; miRTarBase -0.56 0 NA
63 hsa-miR-335-5p CDKN1A 1.77 0 -1.29 0 miRNAWalker2 validate -0.15 2.0E-5 NA
64 hsa-miR-345-5p CDKN1A 3.64 0 -1.29 0 miRNAWalker2 validate; miRTarBase -0.21 0 NA
65 hsa-miR-363-3p CDKN1A 1.51 0.00021 -1.29 0 miRNAWalker2 validate; miRTarBase -0.12 0.00029 NA
66 hsa-miR-423-3p CDKN1A 2.58 0 -1.29 0 miRNAWalker2 validate; miRTarBase -0.2 6.0E-5 NA
67 hsa-miR-503-5p CDKN1A 3.67 0 -1.29 0 miRNAWalker2 validate; miRTarBase -0.11 0.00188 NA
68 hsa-miR-505-5p CDKN1A 1.89 0 -1.29 0 miRNAWalker2 validate -0.2 3.0E-5 NA
69 hsa-miR-93-5p CDKN1A 3.04 0 -1.29 0 miRNAWalker2 validate; miRTarBase -0.23 0 25633810 MicroRNA 93 activates c Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A; We confirmed that miR-93 directly bound with the 3' untranslated regions of the tumor-suppressor genes PTEN and CDKN1A respectivelyand inhibited their expression; We concluded that miR-93 stimulated cell proliferation migration and invasion through the oncogenic c-Met/PI3K/Akt pathway and also inhibited apoptosis by directly inhibiting PTEN and CDKN1A expression in human HCC
70 hsa-miR-942-5p CDKN1A 2.35 0 -1.29 0 miRNAWalker2 validate -0.26 0 NA
71 hsa-miR-96-5p CDKN1A 4.89 0 -1.29 0 miRNAWalker2 validate; miRTarBase -0.13 2.0E-5 26582573 Upregulation of microRNA 96 and its oncogenic functions by targeting CDKN1A in bladder cancer; Bioinformatics prediction combined with luciferase reporter assay were used to verify whether the cyclin-dependent kinase inhibitor CDKN1A was a potential target gene of miR-96; According to the data of miRTarBase CDKN1A might be a candidate target gene of miR-96; In addition luciferase reporter and Western blot assays respectively demonstrated that miR-96 could bind to the putative seed region in CDKN1A mRNA 3'UTR and significantly reduce the expression level of CDKN1A protein; Moreover we found that the inhibition of miR-96 expression remarkably decreased cell proliferation and promoted cell apoptosis of BC cell lines which was consistent with the findings observed following the introduction of CDKN1A cDNA without 3'UTR restored miR-96; Upregulation of miR-96 may contribute to aggressive malignancy partly through suppressing CDKN1A protein expression in BC cells
72 hsa-miR-98-5p CDKN1A 1.11 0 -1.29 0 miRNAWalker2 validate -0.25 0.00026 NA
73 hsa-miR-221-3p CDKN1B 0.45 0.09098 0.11 0.45385 miRNAWalker2 validate; miRTarBase -0.11 6.0E-5 23637992; 19953484; 23939688; 19126397; 20146005; 23967190; 17569667; 22992757; 17721077; 20461750 miR-221 knockdown not only blocked cell cycle progression induced cell apoptosis and inhibited cell proliferation in-vitro but it also inhibited in-vivo tumor growth by targeting p27kip1;Based on bioinformatic analysis we found that the seed sequences of miR-221 and miR-222 coincide with each other and p27kip1 is a target for miRNA-221/222;A Slug/miR-221 network has been suggested linking miR-221 activity with the downregulation of a Slug repressor leading to Slug/miR-221 upregulation and p27Kip1 downregulation; Interference with this process can be achieved using antisense miRNA antagomiR molecules targeting miR-221 inducing the downregulation of Slug and the upregulation of p27Kip1;Moreover a series of functional assays demonstrated that mir-221 could directly inhibit cKit p27Kip1 and possibly other pivotal proteins in melanoma;Matched HCC and adjacent non-cancerous samples were assayed for the expression of miR-221 and three G1/S transition inhibitors: p27Kip1 p21WAF1/Cip1and TGF-β1 by in situ hybridization and immunohistochemistry respectively; Real time qRT-PCR was used to investigate miR-221 and p27Kip1 transcripts in different clinical stages; In result miR-221 and TGF-β1 are frequently up-regulated in HCC while p27Kip1 and p21WAF1/Cip1 proteins are frequently down-regulated; In conclusion miR-221 is important in tumorigenesis of HCC possibly by specifically down-regulating p27Kip1 a cell-cycle inhibitor;Additionally the PDGF-dependent increase in cell proliferation appears to be mediated by inhibition of a specific target of miR-221 and down-regulation of p27Kip1;miR 221 and miR 222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1; In all cell lines tested we show an inverse relationship between the expression of miR-221 and miR-222 and the cell cycle inhibitor p27Kip1; Consistently miR-221 and miR-222 knock-down through antisense LNA oligonucleotides increases p27Kip1 in PC3 cells and strongly reduces their clonogenicity in vitro;Peptide nucleic acids targeting miR 221 modulate p27Kip1 expression in breast cancer MDA MB 231 cells; Targeting miR-221 by PNA resulted in i lowering of the hybridization levels of miR-221 measured by RT-qPCR ii upregulation of p27Kip1 gene expression measured by RT-qPCR and western blot analysis;Antagonism of either microRNA 221 or 222 in glioblastoma cells also caused an increase in p27Kip1 levels and enhanced expression of the luciferase reporter gene fused to the p27Kip1 3'UTR;MiR 221 and MiR 222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B CDKNIC and overall survival; miR-221 and miR-222 negatively regulate expression of CDKN1B p27 and CDKN1C p57 two cell cycle regulators expressed in ovarian surface epithelium and down-regulated in ovarian carcinomas; In contrast CDKN1B expression was not associated with miR-221 or miR-222 expression
74 hsa-miR-24-3p CDKN1B 1 0 0.11 0.45385 miRNAWalker2 validate -0.16 3.0E-5 26847530; 26044523 The biological significance of miR-24 expression in prostate cancer cells was assessed by a series of in vitro bioassays and the effect on proposed targets p27 CDKN1B and p16 CDK2NA was investigated;With the bioinformatic method we further identified that p27Kip1 is a direct target of miR-24-3p and its protein level was negatively regulated by miR-24-3p
75 hsa-miR-221-3p CDKN1C 0.45 0.09098 -1.45 4.0E-5 miRNAWalker2 validate; miRTarBase -0.25 0.00011 20461750 miR-221 and miR-222 negatively regulate expression of CDKN1B p27 and CDKN1C p57 two cell cycle regulators expressed in ovarian surface epithelium and down-regulated in ovarian carcinomas; Higher miR-222 and miR-221 expression were significantly associated with decreased CDKN1C expression P = 0.009 and 0.01
76 hsa-miR-222-3p CDKN1C 0.85 0.00267 -1.45 4.0E-5 miRNAWalker2 validate; miRTarBase -0.25 4.0E-5 20461750 miR-221 and miR-222 negatively regulate expression of CDKN1B p27 and CDKN1C p57 two cell cycle regulators expressed in ovarian surface epithelium and down-regulated in ovarian carcinomas; Higher miR-222 and miR-221 expression were significantly associated with decreased CDKN1C expression P = 0.009 and 0.01
77 hsa-miR-25-3p CDKN1C 1.36 0 -1.45 4.0E-5 miRNAWalker2 validate; miRTarBase -0.16 0.04449 NA
78 hsa-miR-335-5p CDKN1C 1.77 0 -1.45 4.0E-5 miRNAWalker2 validate -0.1 0.02146 NA
79 hsa-miR-10b-5p CDKN2A -0.16 0.55501 2.5 0.00259 miRNAWalker2 validate; miRTarBase -0.4 0.01005 NA
80 hsa-miR-34a-5p CDKN2C 1.9 0 0.23 0.43313 miRNAWalker2 validate -0.22 6.0E-5 NA
81 hsa-miR-23b-3p E2F1 -0.25 0.1502 2.3 0 miRNAWalker2 validate -0.37 1.0E-5 NA
82 hsa-miR-125b-5p E2F3 -1.16 0.00029 0.86 0.00039 miRNAWalker2 validate; miRTarBase -0.14 9.0E-5 20549700; 22523546 E2F3 which was critical for G1/S transition and was overexpressed in most of poor-differentiated bladder cancers was identified as a target of miR-125b by luciferase assay; Introduction of miR-125b could reduce the expression of E2F3 protein but not the E2F3 mRNA;Moreover we demonstrated that the E2F3 was a direct target of miR-125b in breast cancer cells
83 hsa-miR-140-5p EP300 0.84 4.0E-5 -0.26 0.13065 miRNAWalker2 validate -0.12 0.00415 NA
84 hsa-miR-193b-3p EP300 2.26 0 -0.26 0.13065 miRNAWalker2 validate -0.11 8.0E-5 NA
85 hsa-miR-374a-5p GADD45A 0.48 0.0043 -0.84 0.00014 miRNAWalker2 validate; miRTarBase -0.16 0.01486 NA
86 hsa-miR-145-5p HDAC2 -1.55 0 0.31 0.0174 miRNAWalker2 validate -0.11 0 23499894 MiR 145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer; Ectopic expression of miRNA mimics evidenced that miR-145 suppresses HDAC2 expression in HCC cells; In conclusion we suggest that loss or suppression of miR-145 may cause aberrant overexpression of HDAC2 and promote HCC tumorigenesis
87 hsa-let-7f-5p MYC 0.5 0.00356 -1.77 0 miRNAWalker2 validate -0.3 0.00594 NA
88 hsa-let-7g-5p MYC 1.2 0 -1.77 0 miRNAWalker2 validate; miRTarBase -0.65 0 NA
89 hsa-miR-320a MYC 0.44 0.03902 -1.77 0 miRNAWalker2 validate -0.27 0.00203 25736597 Furthermore progesterone P4 promoted the expression of miR-320a by repressing c-Myc expression while estrogen E2 exerted the opposite effect
90 hsa-miR-320b MYC 1.56 0 -1.77 0 miRNAWalker2 validate -0.21 0.00143 26487644 miR 320b suppresses cell proliferation by targeting c Myc in human colorectal cancer cells; Overexpression of miR-320b in CRC cells was statistically correlated with a decrease of cell growth in vitro and in vivo while c-MYC was identified as a target gene of miR-320b in CRC; Furthermore it was found that up-regulation of c-Myc can attenuate the effects induced by miR-320b; Our identification of c-MYC as a target gene of miR-320b provides new insights into the pathophysiology of CRC proliferation and identifies miR-320b as a novel therapeutic target for the treatment of CRC
91 hsa-miR-335-5p MYC 1.77 0 -1.77 0 miRNAWalker2 validate -0.16 0.00141 NA
92 hsa-miR-34a-5p MYC 1.9 0 -1.77 0 miRNAWalker2 validate; miRTarBase -0.36 0 25572695; 25686834; 21460242; 22159222; 23640973; 22830357; 22235332 The c-Myc and CD44 were confirmed as direct targets of miR-34a in EJ cell apoptosis induced by PRE;miR 34a induces cellular senescence via modulation of telomerase activity in human hepatocellular carcinoma by targeting FoxM1/c Myc pathway;Myc mediated repression of microRNA 34a promotes high grade transformation of B cell lymphoma by dysregulation of FoxP1;MicroRNA 34a suppresses malignant transformation by targeting c Myc transcriptional complexes in human renal cell carcinoma; We investigated the functional effects of microRNA-34a miR-34a on c-Myc transcriptional complexes in renal cell carcinoma; miR-34a down-regulated expression of multiple oncogenes including c-Myc by targeting its 3' untranslated region which was revealed by luciferase reporter assays; Our results demonstrate that miR-34a suppresses assembly and function of the c-Myc complex that activates or elongates transcription indicating a novel role of miR-34a in the regulation of transcription by c-Myc;Among them miR-34a was also associated with poor prognosis in 2 independent series of leukemic and nodal MCL and in cooperation with high expression of the MYC oncogene;We report that miR-34a did not inhibit cell proliferation notwithstanding a marked down-regulation of c-MYC;MicroRNA 34a modulates c Myc transcriptional complexes to suppress malignancy in human prostate cancer cells; We studied the functional effects of miR-34a on c-Myc transcriptional complexes in PC-3 prostate cancer cells; miR-34a downregulated expression of c-Myc oncogene by targeting its 3' UTR as shown by luciferase reporter assays; This is the first report to document that miR-34a suppresses assembly and function of the c-Myc-Skp2-Miz1 complex that activates RhoA and the c-Myc-pTEFB complex that elongates transcription of various genes suggesting a novel role of miR-34a in the regulation of transcription by c-Myc complex
93 hsa-miR-423-5p MYC 0.96 0 -1.77 0 miRNAWalker2 validate -0.59 0 NA
94 hsa-miR-429 MYC 4.49 0 -1.77 0 miRNAWalker2 validate -0.27 0 21684154; 24633485 miR 429 modulates the expression of c myc in human gastric carcinoma cells; SGC-7901 gastric cancer cells were transfected with miR-429 mimics and endogenous c-myc expression was detected by western blots; We performed functional assays using the 3'UTR of the c-myc gene as a miR-429 target in a luciferase reporter assay system; miR-429 significantly downregulated endogenous c-myc expression in SGC-7901 cells; Action of miR/429 on c-myc 3'UTR was confirmed; c-myc is an important miR-429 target gene;It is known that miR-429 is down-regulated and functions as a tumor suppressor by targeting c-myc and PLGG1 in gastric and breast cancer
95 hsa-miR-744-5p MYC 1.48 0 -1.77 0 miRNAWalker2 validate -0.25 0.00044 24991193 Decrease expression of microRNA 744 promotes cell proliferation by targeting c Myc in human hepatocellular carcinoma; Quantitative reverse-transcription polymerase chain reaction qRT-PCR was conducted to detect the expression of miR-744 and Immunohistochemistry was performed to detect expression of c-Myc in HCC specimens and adjacent normal tissues; Luciferase reporter assays was performed to confirm whether miR-744 regulated the expression of c-Myc; Luciferase assay and Western blot analysis revealed that c-Myc is a direct target of miR-744; Down-regulation of miR-744 and up-regulation of c-Myc were detected in HCC specimens compared with adjacent normal tissues; Moreover restoration of miR-744 rescues c-Myc induced HCC proliferation; Our data suggest that miR-744 exerts its tumor suppressor function by targeting c-Myc leading to the inhibition of HCC cell growth
96 hsa-miR-98-5p MYC 1.11 0 -1.77 0 miRNAWalker2 validate; miRTarBase -0.6 0 NA
97 hsa-miR-106a-5p RB1 2.49 0 -0.45 0.06418 miRNAWalker2 validate; miRTarBase -0.21 0 NA
98 hsa-miR-106b-5p RB1 2.47 0 -0.45 0.06418 miRNAWalker2 validate; miRTarBase -0.18 8.0E-5 NA
99 hsa-miR-17-5p RB1 3.27 0 -0.45 0.06418 miRNAWalker2 validate; miRTarBase; TargetScan -0.18 0 NA
100 hsa-miR-192-5p RB1 2.69 0 -0.45 0.06418 miRNAWalker2 validate; miRTarBase -0.15 1.0E-5 NA
101 hsa-miR-20a-5p RB1 3.16 0 -0.45 0.06418 miRNAWalker2 validate; miRTarBase -0.18 0 NA
102 hsa-miR-93-5p RB1 3.04 0 -0.45 0.06418 miRNAWalker2 validate -0.17 1.0E-5 NA
103 hsa-miR-155-5p SMAD3 1.2 0.00086 -0.15 0.56924 miRNAWalker2 validate -0.17 0 27626488 Here we demonstrated that TGF-β1 elevated the expression of miR-155 in colorectal cancer cells through SMAD3 and SMAD4
104 hsa-miR-18a-5p SMAD3 3.79 0 -0.15 0.56924 miRNAWalker2 validate -0.14 6.0E-5 23249750 The unexpected effects of miR-18a on CTGF transcription are mediated in part by direct targeting of Smad3 and ensuing weakening of TGFβ signaling
105 hsa-miR-186-5p SMAD4 1.47 0 -0.59 0 miRNAWalker2 validate -0.11 0.00087 NA
106 hsa-miR-320a SMC1A 0.44 0.03902 0.04 0.7733 miRNAWalker2 validate -0.12 0.00036 NA
107 hsa-miR-26b-5p STAG1 0.89 0 -0.25 0.20245 miRNAWalker2 validate -0.17 0.00045 NA
108 hsa-miR-21-5p STAG2 2.74 0 -0.34 0.12258 miRNAWalker2 validate -0.12 0.01253 NA
109 hsa-miR-744-5p TGFB1 1.48 0 -0 0.99941 miRNAWalker2 validate -0.23 1.0E-5 NA
110 hsa-miR-141-3p TGFB2 5.02 0 -1.2 0.00331 miRNAWalker2 validate; miRTarBase; TargetScan -0.36 0 NA
111 hsa-miR-29b-3p TGFB2 1.66 0 -1.2 0.00331 miRTarBase -0.23 0.00122 NA
112 hsa-miR-335-5p TGFB2 1.77 0 -1.2 0.00331 miRNAWalker2 validate -0.25 0 NA
113 hsa-miR-10a-5p TGFB3 1.15 0.00372 -1.92 0 miRNAWalker2 validate -0.42 0 NA
114 hsa-miR-29b-3p TGFB3 1.66 0 -1.92 0 miRTarBase -0.4 0 NA
115 hsa-miR-221-3p TP53 0.45 0.09098 0.17 0.48779 miRNAWalker2 validate -0.12 0.01057 20880178; 24324033 Circulating miR 221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression; The correlation between miR-221 levels and protein levels of p53 CEA ER and PR clinicopathological features or overall survival was analyzed; The immunohistochemistry analysis demonstrates a significant correlation between plasma miR-221 level and p53 expression; The direct amplification of plasma miR-221 can be used as a potential noninvasive molecular marker for diagnosis and prognosis of CRC and is correlated with p53 expression;Interestingly miR-221 can activate the p53/mdm2 axis by inhibiting MDM2 and in turn p53 activation contributes to miR-221 enhanced expression; Moreover by modulating the p53 axis miR-221 impacts cell-cycle progression and apoptotic response to doxorubicin in hepatocellular carcinoma-derived cell lines; These data were confirmed in clinical specimens of hepatocellular carcinoma in which elevated miR-221 expression was associated with the simultaneous presence of wild-type p53 and DNA hypomethylation
116 hsa-miR-222-3p TP53 0.85 0.00267 0.17 0.48779 miRNAWalker2 validate -0.12 0.0059 NA
117 hsa-miR-155-5p WEE1 1.2 0.00086 -1.41 0 miRNAWalker2 validate -0.12 3.0E-5 NA
118 hsa-miR-27a-3p WEE1 1.67 0 -1.41 0 miRTarBase -0.15 0.00064 NA
119 hsa-miR-424-5p WEE1 1.62 0 -1.41 0 miRNAWalker2 validate; miRTarBase -0.13 0.00073 NA
120 hsa-miR-26a-5p YWHAE 0.05 0.75263 0.51 0.00018 miRNAWalker2 validate -0.17 0.00016 NA
121 hsa-miR-103a-3p YWHAH 1.44 0 -0.04 0.78793 miRNAWalker2 validate -0.16 0 NA

Over-represented Gene Ontology Biological Process

NumGOOverlapSizeP ValueAdj. P Value
1 CELL CYCLE 31 1316 6.724e-33 3.129e-29
2 CELL CYCLE PROCESS 28 1081 1.102e-29 2.564e-26
3 REGULATION OF CELL CYCLE 27 949 2.077e-29 3.221e-26
4 NEGATIVE REGULATION OF CELL CYCLE 21 433 1.202e-26 1.398e-23
5 MITOTIC CELL CYCLE 24 766 1.957e-26 1.821e-23
6 CELL CYCLE ARREST 15 154 2.809e-23 2.178e-20
7 POSITIVE REGULATION OF CELL CYCLE 17 332 1.269e-21 8.435e-19
8 REGULATION OF MITOTIC CELL CYCLE 18 468 1.007e-20 5.857e-18
9 CELL CYCLE PHASE TRANSITION 15 255 6.545e-20 3.384e-17
10 NEGATIVE REGULATION OF MITOTIC CELL CYCLE 14 199 1.134e-19 5.276e-17
11 REGULATION OF PROTEIN MODIFICATION PROCESS 25 1710 1.336e-19 5.65e-17
12 REGULATION OF CELL PROLIFERATION 23 1496 3.725e-18 1.444e-15
13 MITOTIC CELL CYCLE CHECKPOINT 12 139 5.698e-18 2.04e-15
14 CELL DIVISION 16 460 1.288e-17 4.28e-15
15 REGULATION OF PHOSPHORUS METABOLIC PROCESS 23 1618 2.123e-17 6.584e-15
16 REGULATION OF CELL CYCLE ARREST 11 108 2.528e-17 7.351e-15
17 NEGATIVE REGULATION OF CELL PROLIFERATION 17 643 9.006e-17 2.465e-14
18 REGULATION OF TRANSFERASE ACTIVITY 19 946 1.103e-16 2.851e-14
19 POSITIVE REGULATION OF CELL CYCLE PROCESS 13 247 1.314e-16 3.218e-14
20 POSITIVE REGULATION OF CELL CYCLE ARREST 10 85 1.873e-16 4.358e-14
21 REGULATION OF CELL CYCLE PROCESS 16 558 2.712e-16 6.008e-14
22 CELL CYCLE CHECKPOINT 12 194 3.381e-16 7.151e-14
23 SIGNAL TRANSDUCTION IN RESPONSE TO DNA DAMAGE 10 96 6.668e-16 1.349e-13
24 NEGATIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION 10 98 8.261e-16 1.602e-13
25 POSITIVE REGULATION OF CELL DEATH 16 605 9.634e-16 1.793e-13
26 NEGATIVE REGULATION OF CELL CYCLE PROCESS 12 214 1.11e-15 1.987e-13
27 NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS 16 616 1.277e-15 2.201e-13
28 NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS 19 1087 1.414e-15 2.35e-13
29 POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 21 1492 1.561e-15 2.505e-13
30 CELL CYCLE G1 S PHASE TRANSITION 10 111 2.995e-15 4.496e-13
31 G1 S TRANSITION OF MITOTIC CELL CYCLE 10 111 2.995e-15 4.496e-13
32 POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 19 1135 3.113e-15 4.527e-13
33 REGULATION OF CELL CYCLE PHASE TRANSITION 13 321 3.958e-15 5.581e-13
34 G1 DNA DAMAGE CHECKPOINT 9 73 4.515e-15 6.179e-13
35 NEGATIVE REGULATION OF CELL CYCLE PHASE TRANSITION 10 146 4.941e-14 6.569e-12
36 REGULATION OF CELL CYCLE G1 S PHASE TRANSITION 10 147 5.296e-14 6.845e-12
37 MITOTIC DNA INTEGRITY CHECKPOINT 9 100 8.571e-14 1.078e-11
38 RESPONSE TO OXYGEN LEVELS 12 311 9.805e-14 1.201e-11
39 RESPONSE TO ABIOTIC STIMULUS 17 1024 1.899e-13 2.266e-11
40 POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 17 1036 2.294e-13 2.603e-11
41 POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 17 1036 2.294e-13 2.603e-11
42 REGULATION OF KINASE ACTIVITY 15 776 9.371e-13 1.038e-10
43 POSITIVE REGULATION OF CELL PROLIFERATION 15 814 1.862e-12 1.969e-10
44 REGULATION OF ORGANELLE ORGANIZATION 17 1178 1.823e-12 1.969e-10
45 DNA INTEGRITY CHECKPOINT 9 146 2.757e-12 2.851e-10
46 NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 13 541 3.082e-12 3.051e-10
47 NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 13 541 3.082e-12 3.051e-10
48 REGULATION OF CELLULAR PROTEIN LOCALIZATION 13 552 3.97e-12 3.848e-10
49 REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 8 97 4.82e-12 4.577e-10
50 REGULATION OF CELL DEATH 18 1472 4.92e-12 4.579e-10
51 NEGATIVE REGULATION OF MOLECULAR FUNCTION 16 1079 7.099e-12 6.477e-10
52 NEGATIVE REGULATION OF CELL GROWTH 9 170 1.093e-11 9.783e-10
53 NEGATIVE REGULATION OF TRANSFERASE ACTIVITY 11 351 1.192e-11 1.046e-09
54 REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 12 470 1.261e-11 1.087e-09
55 POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION 11 360 1.565e-11 1.324e-09
56 MITOTIC NUCLEAR DIVISION 11 361 1.612e-11 1.34e-09
57 POSITIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION 6 34 2.374e-11 1.904e-09
58 ORGANELLE FISSION 12 496 2.357e-11 1.904e-09
59 CELL DEATH 15 1001 3.535e-11 2.788e-09
60 REGULATION OF CELL GROWTH 11 391 3.797e-11 2.945e-09
61 NEGATIVE REGULATION OF CATALYTIC ACTIVITY 14 829 4.088e-11 3.118e-09
62 SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 8 127 4.312e-11 3.236e-09
63 POSITIVE REGULATION OF GENE EXPRESSION 18 1733 7.524e-11 5.557e-09
64 NEGATIVE REGULATION OF PHOSPHORYLATION 11 422 8.58e-11 6.238e-09
65 NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS 17 1517 1.014e-10 7.26e-09
66 POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 18 1805 1.475e-10 1.026e-08
67 DIGESTIVE SYSTEM DEVELOPMENT 8 148 1.477e-10 1.026e-08
68 NEGATIVE REGULATION OF GROWTH 9 236 2.059e-10 1.409e-08
69 REGULATION OF DNA METABOLIC PROCESS 10 340 2.225e-10 1.5e-08
70 REGULATION OF PROTEIN LOCALIZATION 14 950 2.468e-10 1.641e-08
71 POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 15 1152 2.542e-10 1.666e-08
72 POSITIVE REGULATION OF STEM CELL DIFFERENTIATION 6 50 2.749e-10 1.777e-08
73 POSITIVE REGULATION OF TRANSFERASE ACTIVITY 12 616 2.861e-10 1.823e-08
74 REGULATION OF INTRACELLULAR TRANSPORT 12 621 3.138e-10 1.973e-08
75 POSITIVE REGULATION OF KINASE ACTIVITY 11 482 3.52e-10 2.184e-08
76 POSITIVE REGULATION OF INTRACELLULAR TRANSPORT 10 370 5.061e-10 3.098e-08
77 POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION 11 514 6.937e-10 4.192e-08
78 REGULATION OF CELL DIFFERENTIATION 16 1492 8.843e-10 5.275e-08
79 GLAND DEVELOPMENT 10 395 9.529e-10 5.613e-08
80 REGULATION OF EPITHELIAL CELL PROLIFERATION 9 285 1.09e-09 6.341e-08
81 APOPTOTIC SIGNALING PATHWAY 9 289 1.232e-09 7.079e-08
82 RESPONSE TO LIPID 13 888 1.422e-09 8.067e-08
83 CELLULAR RESPONSE TO DNA DAMAGE STIMULUS 12 720 1.686e-09 9.363e-08
84 REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION 6 67 1.69e-09 9.363e-08
85 INTRACELLULAR SIGNAL TRANSDUCTION 16 1572 1.897e-09 1.038e-07
86 RESPONSE TO ORGANIC CYCLIC COMPOUND 13 917 2.099e-09 1.136e-07
87 POSITIVE REGULATION OF ORGANELLE ORGANIZATION 11 573 2.169e-09 1.16e-07
88 RESPONSE TO DRUG 10 431 2.208e-09 1.168e-07
89 POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS 7 129 2.281e-09 1.192e-07
90 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE 6 71 2.414e-09 1.248e-07
91 REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS 8 218 3.202e-09 1.637e-07
92 REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 8 220 3.441e-09 1.74e-07
93 CELL CYCLE G2 M PHASE TRANSITION 7 138 3.656e-09 1.829e-07
94 REPLICATIVE SENESCENCE 4 12 3.85e-09 1.906e-07
95 POSITIVE REGULATION OF RESPONSE TO STIMULUS 17 1929 4.204e-09 2.059e-07
96 POSITIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 5 36 4.417e-09 2.141e-07
97 REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 16 1672 4.643e-09 2.227e-07
98 REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 9 337 4.726e-09 2.244e-07
99 REGULATION OF FIBROBLAST PROLIFERATION 6 81 5.402e-09 2.539e-07
100 NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS 12 801 5.599e-09 2.605e-07
101 REGULATION OF GROWTH 11 633 6.119e-09 2.791e-07
102 RESPONSE TO ENDOGENOUS STIMULUS 15 1450 6.075e-09 2.791e-07
103 RESPONSE TO STEROID HORMONE 10 497 8.625e-09 3.896e-07
104 NEGATIVE REGULATION OF GENE EXPRESSION 15 1493 9.04e-09 4.045e-07
105 NEGATIVE REGULATION OF KINASE ACTIVITY 8 250 9.371e-09 4.153e-07
106 REGULATION OF DNA REPLICATION 7 161 1.069e-08 4.694e-07
107 POSITIVE REGULATION OF CATALYTIC ACTIVITY 15 1518 1.132e-08 4.852e-07
108 REGULATION OF CELLULAR LOCALIZATION 14 1277 1.137e-08 4.852e-07
109 POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 7 162 1.116e-08 4.852e-07
110 POSITIVE REGULATION OF MOLECULAR FUNCTION 16 1791 1.249e-08 5.284e-07
111 POSITIVE REGULATION OF CELL COMMUNICATION 15 1532 1.282e-08 5.375e-07
112 REGULATION OF CELL DIVISION 8 272 1.808e-08 7.512e-07
113 REGULATION OF BINDING 8 283 2.46e-08 1.013e-06
114 RESPONSE TO RADIATION 9 413 2.747e-08 1.121e-06
115 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 13 1142 2.911e-08 1.178e-06
116 NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 11 740 3.06e-08 1.228e-06
117 POSITIVE REGULATION OF FIBROBLAST PROLIFERATION 5 53 3.291e-08 1.309e-06
118 NEGATIVE REGULATION OF DNA METABOLIC PROCESS 6 111 3.631e-08 1.432e-06
119 NEUROGENESIS 14 1402 3.714e-08 1.452e-06
120 IMMUNE SYSTEM DEVELOPMENT 10 582 3.841e-08 1.489e-06
121 NEGATIVE REGULATION OF DNA REPLICATION 5 55 3.98e-08 1.531e-06
122 REGULATION OF STEM CELL DIFFERENTIATION 6 113 4.041e-08 1.541e-06
123 SMAD PROTEIN SIGNAL TRANSDUCTION 5 56 4.365e-08 1.651e-06
124 NEGATIVE REGULATION OF EPITHELIAL CELL PROLIFERATION 6 115 4.489e-08 1.685e-06
125 CELL DEVELOPMENT 14 1426 4.599e-08 1.712e-06
126 NEGATIVE REGULATION OF CELL DIFFERENTIATION 10 609 5.878e-08 2.171e-06
127 REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 7 207 6.045e-08 2.212e-06
128 POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 6 121 6.086e-08 2.212e-06
129 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL METABOLIC PROCESS 4 23 6.795e-08 2.432e-06
130 POSITIVE REGULATION OF COLLAGEN METABOLIC PROCESS 4 23 6.795e-08 2.432e-06
131 POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 12 1004 6.847e-08 2.432e-06
132 CELLULAR RESPONSE TO ENDOGENOUS STIMULUS 12 1008 7.152e-08 2.521e-06
133 CHROMOSOME ORGANIZATION 12 1009 7.23e-08 2.53e-06
134 NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 6 126 7.751e-08 2.691e-06
135 RESPONSE TO GROWTH FACTOR 9 475 9.091e-08 3.133e-06
136 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 15 1784 9.857e-08 3.372e-06
137 REGULATION OF CYTOPLASMIC TRANSPORT 9 481 1.012e-07 3.436e-06
138 CELLULAR RESPONSE TO RADIATION 6 137 1.276e-07 4.302e-06
139 REPRODUCTION 13 1297 1.299e-07 4.35e-06
140 CELLULAR RESPONSE TO STRESS 14 1565 1.471e-07 4.887e-06
141 NEGATIVE REGULATION OF CELL DEATH 11 872 1.621e-07 5.349e-06
142 POSITIVE REGULATION OF PROTEOLYSIS 8 363 1.673e-07 5.481e-06
143 RESPONSE TO TRANSFORMING GROWTH FACTOR BETA 6 144 1.715e-07 5.58e-06
144 RESPONSE TO IONIZING RADIATION 6 145 1.787e-07 5.687e-06
145 REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 29 1.809e-07 5.687e-06
146 POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 29 1.809e-07 5.687e-06
147 REGULATION OF EXTRACELLULAR MATRIX ORGANIZATION 4 29 1.809e-07 5.687e-06
148 REGULATION OF HEART MORPHOGENESIS 4 29 1.809e-07 5.687e-06
149 POSITIVE REGULATION OF CHROMOSOME ORGANIZATION 6 150 2.184e-07 6.819e-06
150 INTRINSIC APOPTOTIC SIGNALING PATHWAY 6 152 2.362e-07 7.326e-06
151 REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 8 381 2.419e-07 7.455e-06
152 REGULATION OF PROTEOLYSIS 10 711 2.482e-07 7.599e-06
153 AGING 7 264 3.162e-07 9.617e-06
154 TUBE DEVELOPMENT 9 552 3.241e-07 9.728e-06
155 REGULATION OF CELL MORPHOGENESIS 9 552 3.241e-07 9.728e-06
156 POSITIVE REGULATION OF TRANSPORT 11 936 3.299e-07 9.839e-06
157 REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 6 162 3.44e-07 1.019e-05
158 EPITHELIUM DEVELOPMENT 11 945 3.629e-07 1.062e-05
159 POSITIVE REGULATION OF CHROMATIN MODIFICATION 5 85 3.615e-07 1.062e-05
160 GROWTH 8 410 4.222e-07 1.228e-05
161 POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 36 4.448e-07 1.285e-05
162 REGULATION OF CHROMOSOME ORGANIZATION 7 278 4.481e-07 1.287e-05
163 POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 6 171 4.728e-07 1.35e-05
164 POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT 7 282 4.933e-07 1.4e-05
165 REGULATION OF MULTICELLULAR ORGANISMAL METABOLIC PROCESS 4 38 5.56e-07 1.568e-05
166 POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 7 289 5.817e-07 1.631e-05
167 TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY 5 95 6.305e-07 1.757e-05
168 RESPONSE TO KETONE 6 182 6.816e-07 1.888e-05
169 REGULATION OF PROTEIN IMPORT 6 183 7.039e-07 1.938e-05
170 REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY 5 99 7.745e-07 2.095e-05
171 REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS 5 99 7.745e-07 2.095e-05
172 MEIOTIC CELL CYCLE 6 186 7.741e-07 2.095e-05
173 POSITIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 5 100 8.142e-07 2.19e-05
174 REGULATION OF PROTEIN TARGETING 7 307 8.722e-07 2.332e-05
175 REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 43 9.238e-07 2.456e-05
176 POSITIVE REGULATION OF PROTEIN IMPORT 5 104 9.896e-07 2.616e-05
177 REGULATION OF MACROPHAGE CYTOKINE PRODUCTION 3 12 1.068e-06 2.793e-05
178 POSITIVE REGULATION OF SMAD PROTEIN IMPORT INTO NUCLEUS 3 12 1.068e-06 2.793e-05
179 CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND 8 465 1.09e-06 2.827e-05
180 REGULATION OF CELL DEVELOPMENT 10 836 1.094e-06 2.827e-05
181 CELLULAR RESPONSE TO ORGANIC SUBSTANCE 14 1848 1.128e-06 2.899e-05
182 PEPTIDYL AMINO ACID MODIFICATION 10 841 1.154e-06 2.951e-05
183 SISTER CHROMATID COHESION 5 111 1.367e-06 3.476e-05
184 MITOTIC CELL CYCLE ARREST 3 13 1.387e-06 3.508e-05
185 POSITIVE REGULATION OF PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION 4 48 1.447e-06 3.641e-05
186 NOTCH SIGNALING PATHWAY 5 114 1.56e-06 3.903e-05
187 PROTEIN SUMOYLATION 5 115 1.629e-06 4.053e-05
188 SENSORY ORGAN DEVELOPMENT 8 493 1.688e-06 4.177e-05
189 REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 6 213 1.706e-06 4.199e-05
190 LYMPHOCYTE ACTIVATION 7 342 1.791e-06 4.386e-05
191 RESPONSE TO ESTROGEN 6 218 1.951e-06 4.754e-05
192 RESPONSE TO HORMONE 10 893 1.985e-06 4.811e-05
193 CELLULAR RESPONSE TO IONIZING RADIATION 4 52 2.004e-06 4.831e-05
194 REGULATION OF CELLULAR RESPONSE TO STRESS 9 691 2.099e-06 5.035e-05
195 INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR 4 53 2.165e-06 5.166e-05
196 POSITIVE REGULATION OF MITOTIC CELL CYCLE 5 123 2.27e-06 5.39e-05
197 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 12 1395 2.336e-06 5.516e-05
198 REGULATION OF IMMUNE SYSTEM PROCESS 12 1403 2.48e-06 5.827e-05
199 NUCLEAR CHROMOSOME SEGREGATION 6 228 2.53e-06 5.916e-05
200 RESPONSE TO UV 5 126 2.557e-06 5.948e-05
201 REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS 6 229 2.595e-06 5.977e-05
202 HEAD DEVELOPMENT 9 709 2.593e-06 5.977e-05
203 RESPONSE TO ALCOHOL 7 362 2.61e-06 5.983e-05
204 REGULATION OF SMAD PROTEIN IMPORT INTO NUCLEUS 3 16 2.707e-06 6.174e-05
205 REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION 5 128 2.763e-06 6.27e-05
206 NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS 7 372 3.125e-06 7.058e-05
207 POSITIVE REGULATION OF CELL DIVISION 5 132 3.214e-06 7.224e-05
208 POSITIVE REGULATION OF EXTRACELLULAR MATRIX ORGANIZATION 3 17 3.283e-06 7.309e-05
209 PROTEIN PHOSPHORYLATION 10 944 3.267e-06 7.309e-05
210 REGULATION OF CELL CYCLE G2 M PHASE TRANSITION 4 59 3.34e-06 7.365e-05
211 REGULATION OF CATABOLIC PROCESS 9 731 3.33e-06 7.365e-05
212 REGULATION OF PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION 4 60 3.574e-06 7.807e-05
213 REGULATION OF ORGAN MORPHOGENESIS 6 242 3.569e-06 7.807e-05
214 SOMITOGENESIS 4 62 4.078e-06 8.868e-05
215 REGULATION OF PROTEIN CATABOLIC PROCESS 7 393 4.485e-06 9.707e-05
216 REGULATION OF CYTOKINE PRODUCTION 8 563 4.514e-06 9.724e-05
217 REGULATION OF PROTEIN ACETYLATION 4 64 4.634e-06 9.936e-05
218 NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 10 983 4.687e-06 1e-04
219 RAS PROTEIN SIGNAL TRANSDUCTION 5 143 4.758e-06 0.0001011
220 CELL ACTIVATION 8 568 4.818e-06 0.0001019
221 REGULATION OF CELLULAR COMPONENT BIOGENESIS 9 767 4.928e-06 0.0001037
222 POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 6 258 5.157e-06 0.0001081
223 CELLULAR RESPONSE TO UV 4 66 5.243e-06 0.0001094
224 POSITIVE REGULATION OF NEURON DEATH 4 67 5.569e-06 0.0001142
225 POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS 7 406 5.553e-06 0.0001142
226 CELL AGING 4 67 5.569e-06 0.0001142
227 REGULATION OF TRANSPORT 13 1804 5.544e-06 0.0001142
228 TISSUE DEVELOPMENT 12 1518 5.627e-06 0.0001148
229 CELLULAR RESPONSE TO ABIOTIC STIMULUS 6 263 5.756e-06 0.000117
230 LEUKOCYTE ACTIVATION 7 414 6.309e-06 0.0001276
231 REGULATION OF CHROMATIN ORGANIZATION 5 152 6.411e-06 0.0001286
232 MEIOTIC CELL CYCLE PROCESS 5 152 6.411e-06 0.0001286
233 REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 10 1021 6.56e-06 0.000131
234 REGULATION OF MEMBRANE PERMEABILITY 4 70 6.637e-06 0.000132
235 CHROMOSOME SEGREGATION 6 272 6.979e-06 0.0001382
236 NEGATIVE REGULATION OF CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE 3 22 7.39e-06 0.0001457
237 POSITIVE REGULATION OF CELL DIFFERENTIATION 9 823 8.715e-06 0.0001711
238 SOMITE DEVELOPMENT 4 78 1.022e-05 0.0001999
239 REGULATION OF TRANSFORMING GROWTH FACTOR BETA PRODUCTION 3 25 1.1e-05 0.0002141
240 RHYTHMIC PROCESS 6 298 1.174e-05 0.0002276
241 CELLULAR RESPONSE TO LIPID 7 457 1.2e-05 0.0002318
242 REGULATION OF CELLULAR SENESCENCE 3 26 1.242e-05 0.0002387
243 GLIOGENESIS 5 175 1.271e-05 0.0002434
244 ORGAN REGENERATION 4 83 1.309e-05 0.0002486
245 SISTER CHROMATID SEGREGATION 5 176 1.307e-05 0.0002486
246 REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 12 1656 1.372e-05 0.0002586
247 POSITIVE REGULATION OF OSSIFICATION 4 84 1.373e-05 0.0002586
248 REGULATION OF OSSIFICATION 5 178 1.38e-05 0.0002589
249 REGULATION OF TRANSCRIPTION INVOLVED IN G1 S TRANSITION OF MITOTIC CELL CYCLE 3 27 1.395e-05 0.0002607
250 POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 9 876 1.438e-05 0.0002676
251 RESPONSE TO OXYGEN CONTAINING COMPOUND 11 1381 1.453e-05 0.0002694
252 POSITIVE REGULATION OF CELL DEVELOPMENT 7 472 1.479e-05 0.0002732
253 CHROMATIN ORGANIZATION 8 663 1.489e-05 0.0002738
254 POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS 4 86 1.507e-05 0.0002761
255 PEPTIDYL LYSINE MODIFICATION 6 312 1.523e-05 0.0002779
256 POSITIVE REGULATION OF LEUKOCYTE APOPTOTIC PROCESS 3 28 1.561e-05 0.0002837
257 CELLULAR RESPONSE TO OXIDATIVE STRESS 5 184 1.62e-05 0.0002932
258 DNA REPAIR 7 480 1.649e-05 0.0002974
259 POSITIVE REGULATION OF DNA METABOLIC PROCESS 5 185 1.663e-05 0.0002987
260 EMBRYO DEVELOPMENT 9 894 1.691e-05 0.0003026
261 SEGMENTATION 4 89 1.726e-05 0.0003078
262 NEGATIVE REGULATION OF PRODUCTION OF MOLECULAR MEDIATOR OF IMMUNE RESPONSE 3 29 1.739e-05 0.0003088
263 MESONEPHROS DEVELOPMENT 4 90 1.804e-05 0.0003192
264 CELLULAR RESPONSE TO LIGHT STIMULUS 4 91 1.885e-05 0.000332
265 TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 5 190 1.891e-05 0.000332
266 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE BY P53 CLASS MEDIATOR 3 30 1.93e-05 0.0003363
267 RESPONSE TO X RAY 3 30 1.93e-05 0.0003363
268 EYE DEVELOPMENT 6 326 1.951e-05 0.0003388
269 MITOCHONDRIAL MEMBRANE ORGANIZATION 4 92 1.968e-05 0.0003404
270 DEVELOPMENTAL MATURATION 5 193 2.039e-05 0.0003513
271 REGULATION OF DNA BINDING 4 93 2.054e-05 0.0003527
272 REGULATION OF DNA BIOSYNTHETIC PROCESS 4 94 2.143e-05 0.0003665
273 REGULATION OF CYTOSKELETON ORGANIZATION 7 502 2.2e-05 0.0003736
274 DEVELOPMENTAL GROWTH 6 333 2.2e-05 0.0003736
275 NEGATIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 3 32 2.352e-05 0.0003965
276 SALIVARY GLAND DEVELOPMENT 3 32 2.352e-05 0.0003965
277 CELLULAR SENESCENCE 3 33 2.584e-05 0.0004309
278 REGULATION OF RESPONSE TO STRESS 11 1468 2.578e-05 0.0004309
279 REGULATION OF CELL AGING 3 33 2.584e-05 0.0004309
280 REGULATION OF PROTEIN DEACETYLATION 3 34 2.831e-05 0.0004704
281 NEGATIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 4 102 2.956e-05 0.0004896
282 LYMPHOCYTE DIFFERENTIATION 5 209 2.988e-05 0.000493
283 RESPONSE TO MINERALOCORTICOID 3 35 3.092e-05 0.0005084
284 POSITIVE REGULATION OF PROTEIN SECRETION 5 211 3.127e-05 0.0005123
285 CELLULAR RESPONSE TO REACTIVE OXYGEN SPECIES 4 104 3.191e-05 0.000521
286 PHOSPHORYLATION 10 1228 3.277e-05 0.0005331
287 POSITIVE REGULATION OF PROTEIN ACETYLATION 3 36 3.369e-05 0.0005443
288 HEAD MORPHOGENESIS 3 36 3.369e-05 0.0005443
289 CHROMATIN MODIFICATION 7 539 3.467e-05 0.0005582
290 REGULATION OF APOPTOTIC SIGNALING PATHWAY 6 363 3.568e-05 0.0005725
291 REGULATION OF MITOCHONDRION ORGANIZATION 5 218 3.655e-05 0.0005844
292 NEGATIVE REGULATION OF PROTEIN CATABOLIC PROCESS 4 109 3.837e-05 0.0006114
293 POSITIVE REGULATION OF BIOMINERAL TISSUE DEVELOPMENT 3 38 3.971e-05 0.0006264
294 MESENCHYME MORPHOGENESIS 3 38 3.971e-05 0.0006264
295 POSITIVE REGULATION OF SECRETION 6 370 3.97e-05 0.0006264
296 EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING 7 554 4.128e-05 0.0006489
297 MULTICELLULAR ORGANISM REPRODUCTION 8 768 4.268e-05 0.0006687
298 REGULATION OF DNA DEPENDENT DNA REPLICATION 3 41 5e-05 0.0007781
299 NEGATIVE REGULATION OF FAT CELL DIFFERENTIATION 3 41 5e-05 0.0007781
300 REGULATION OF PEPTIDASE ACTIVITY 6 392 5.474e-05 0.000849
301 NEGATIVE REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS 4 121 5.773e-05 0.0008894
302 REGULATION OF B CELL ACTIVATION 4 121 5.773e-05 0.0008894
303 RESPONSE TO TOXIC SUBSTANCE 5 241 5.89e-05 0.0009044
304 BODY MORPHOGENESIS 3 44 6.19e-05 0.0009474
305 KIDNEY EPITHELIUM DEVELOPMENT 4 125 6.553e-05 0.0009997
306 EXOCRINE SYSTEM DEVELOPMENT 3 45 6.624e-05 0.001007
307 POSITIVE REGULATION OF BINDING 4 127 6.971e-05 0.001056
308 REGULATION OF NEURON DEATH 5 252 7.275e-05 0.001099
309 RESPONSE TO ANTIBIOTIC 3 47 7.551e-05 0.001133
310 POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS 3 47 7.551e-05 0.001133
311 REGULATION OF LIGASE ACTIVITY 4 130 7.633e-05 0.001142
312 LEUKOCYTE CELL CELL ADHESION 5 255 7.693e-05 0.001147
313 NEGATIVE REGULATION OF RESPONSE TO STIMULUS 10 1360 7.801e-05 0.00116
314 CELL MATURATION 4 131 7.864e-05 0.001162
315 PROTEIN STABILIZATION 4 131 7.864e-05 0.001162
316 ORGAN MORPHOGENESIS 8 841 8.093e-05 0.001192
317 CELL GROWTH 4 135 8.837e-05 0.001297
318 RESPONSE TO ETHANOL 4 136 9.094e-05 0.00131
319 LYMPHOCYTE HOMEOSTASIS 3 50 9.095e-05 0.00131
320 FACE DEVELOPMENT 3 50 9.095e-05 0.00131
321 RESPONSE TO PROGESTERONE 3 50 9.095e-05 0.00131
322 RESPONSE TO GAMMA RADIATION 3 50 9.095e-05 0.00131
323 GLIAL CELL DIFFERENTIATION 4 136 9.094e-05 0.00131
324 RESPONSE TO NITROGEN COMPOUND 8 859 9.384e-05 0.001348
325 NEGATIVE REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL 4 139 9.896e-05 0.001417
326 CENTRAL NERVOUS SYSTEM DEVELOPMENT 8 872 0.0001042 0.001487
327 REGULATION OF HOMEOSTATIC PROCESS 6 447 0.0001129 0.001606
328 REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS 4 145 0.0001165 0.001653
329 RESPONSE TO ESTRADIOL 4 146 0.0001197 0.001687
330 RESPONSE TO LIGHT STIMULUS 5 280 0.0001194 0.001687
331 CRANIAL SKELETAL SYSTEM DEVELOPMENT 3 55 0.000121 0.001696
332 REGULATION OF B CELL PROLIFERATION 3 55 0.000121 0.001696
333 SKELETAL SYSTEM DEVELOPMENT 6 455 0.0001244 0.001738
334 EPITHELIAL TO MESENCHYMAL TRANSITION 3 56 0.0001277 0.001779
335 CHROMATIN REMODELING 4 150 0.0001328 0.001845
336 REGULATION OF CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE 3 57 0.0001346 0.001865
337 CELL PROLIFERATION 7 672 0.0001387 0.001914
338 REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS 4 152 0.0001398 0.001924
339 LEUKOCYTE DIFFERENTIATION 5 292 0.0001453 0.001995
340 POSITIVE REGULATION OF PEPTIDASE ACTIVITY 4 154 0.000147 0.002011
341 LEUKOCYTE HOMEOSTASIS 3 60 0.0001569 0.002141
342 NEURON DEVELOPMENT 7 687 0.0001589 0.002156
343 NEGATIVE REGULATION OF CELL COMMUNICATION 9 1192 0.0001586 0.002156
344 REGULATION OF EXTRACELLULAR MATRIX ASSEMBLY 2 11 0.000162 0.002176
345 REGULATION OF DEPHOSPHORYLATION 4 158 0.0001622 0.002176
346 NEGATIVE REGULATION OF CELLULAR SENESCENCE 2 11 0.000162 0.002176
347 UROGENITAL SYSTEM DEVELOPMENT 5 299 0.0001623 0.002176
348 MEMBRANE DEPOLARIZATION 3 61 0.0001648 0.002191
349 RESPONSE TO INORGANIC SUBSTANCE 6 479 0.0001646 0.002191
350 CELLULAR RESPONSE TO HYDROGEN PEROXIDE 3 61 0.0001648 0.002191
351 REGENERATION 4 161 0.0001744 0.002311
352 POSITIVE REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION 4 162 0.0001786 0.00236
353 REGULATION OF CARTILAGE DEVELOPMENT 3 63 0.0001814 0.002391
354 REGULATION OF NUCLEAR DIVISION 4 163 0.0001828 0.002403
355 RESPONSE TO EXTERNAL STIMULUS 11 1821 0.0001838 0.002409
356 POSITIVE REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS 3 64 0.0001901 0.002485
357 MITOTIC SISTER CHROMATID COHESION 2 12 0.0001942 0.002531
358 IN UTERO EMBRYONIC DEVELOPMENT 5 311 0.0001949 0.002533
359 EPITHELIAL CELL DIFFERENTIATION 6 495 0.0001966 0.002549
360 REGULATION OF ACTIN FILAMENT BASED PROCESS 5 312 0.0001978 0.002557
361 POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION 4 167 0.0002006 0.002586
362 REGULATION OF HEMOPOIESIS 5 314 0.0002038 0.002619
363 NEGATIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS 3 66 0.0002083 0.002656
364 NEGATIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY 3 66 0.0002083 0.002656
365 LENS DEVELOPMENT IN CAMERA TYPE EYE 3 66 0.0002083 0.002656
366 CELLULAR RESPONSE TO DRUG 3 67 0.0002178 0.002769
367 POSITIVE REGULATION OF CELL CYCLE PHASE TRANSITION 3 68 0.0002276 0.002886
368 POSITIVE REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 2 13 0.0002293 0.002891
369 PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION 2 13 0.0002293 0.002891
370 NEGATIVE REGULATION OF LEUKOCYTE PROLIFERATION 3 69 0.0002377 0.002981
371 NEGATIVE REGULATION OF OSSIFICATION 3 69 0.0002377 0.002981
372 CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 6 513 0.0002385 0.002983
373 HOMEOSTASIS OF NUMBER OF CELLS 4 175 0.0002399 0.002993
374 RESPONSE TO CORTICOSTEROID 4 176 0.0002452 0.003051
375 MITOCHONDRIAL TRANSPORT 4 177 0.0002506 0.003109
376 ENDODERM DEVELOPMENT 3 71 0.0002586 0.003201
377 POSITIVE REGULATION OF HISTONE DEACETYLATION 2 14 0.0002672 0.003263
378 DETERMINATION OF ADULT LIFESPAN 2 14 0.0002672 0.003263
379 CRANIOFACIAL SUTURE MORPHOGENESIS 2 14 0.0002672 0.003263
380 REGULATION OF EXTRACELLULAR MATRIX DISASSEMBLY 2 14 0.0002672 0.003263
381 RESPONSE TO LAMINAR FLUID SHEAR STRESS 2 14 0.0002672 0.003263
382 DNA METABOLIC PROCESS 7 758 0.0002904 0.003538
383 CELL JUNCTION ORGANIZATION 4 185 0.0002965 0.003602
384 REGULATION OF BIOMINERAL TISSUE DEVELOPMENT 3 75 0.0003041 0.003685
385 REGULATION OF HAIR FOLLICLE DEVELOPMENT 2 15 0.000308 0.003703
386 NEGATIVE REGULATION OF B CELL PROLIFERATION 2 15 0.000308 0.003703
387 POSITIVE REGULATION OF T CELL APOPTOTIC PROCESS 2 15 0.000308 0.003703
388 REGULATION OF CELLULAR RESPONSE TO HEAT 3 76 0.0003162 0.003792
389 MYELOID CELL DIFFERENTIATION 4 189 0.0003216 0.003847
390 MESENCHYME DEVELOPMENT 4 190 0.0003282 0.003905
391 STEM CELL DIFFERENTIATION 4 190 0.0003282 0.003905
392 NEURON PROJECTION DEVELOPMENT 6 545 0.0003299 0.003916
393 RESPONSE TO REACTIVE OXYGEN SPECIES 4 191 0.0003348 0.003963
394 REGULATION OF NEURON APOPTOTIC PROCESS 4 192 0.0003415 0.004033
395 SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION 5 352 0.0003452 0.004056
396 RESPONSE TO OXIDATIVE STRESS 5 352 0.0003452 0.004056
397 NEGATIVE REGULATION OF DNA DEPENDENT DNA REPLICATION 2 16 0.0003516 0.00411
398 CELLULAR RESPONSE TO ANTIBIOTIC 2 16 0.0003516 0.00411
399 REGULATION OF LEUKOCYTE APOPTOTIC PROCESS 3 79 0.0003544 0.004121
400 REGULATION OF HYDROLASE ACTIVITY 9 1327 0.0003543 0.004121
401 ANTERIOR POSTERIOR PATTERN SPECIFICATION 4 194 0.0003551 0.004121
402 REGULATION OF CELL PROJECTION ORGANIZATION 6 558 0.0003741 0.004331
403 IMMUNE SYSTEM PROCESS 11 1984 0.0003902 0.004505
404 NEGATIVE REGULATION OF CELL AGING 2 17 0.000398 0.004573
405 POSITIVE REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 2 17 0.000398 0.004573
406 SKELETAL SYSTEM MORPHOGENESIS 4 201 0.0004062 0.004655
407 REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY 5 365 0.0004075 0.004659
408 NEGATIVE REGULATION OF CATABOLIC PROCESS 4 203 0.0004216 0.004809
409 POSITIVE REGULATION OF MUSCLE CELL DIFFERENTIATION 3 84 0.0004245 0.004829
410 POSITIVE REGULATION OF CYTOKINE PRODUCTION 5 370 0.0004337 0.004922
411 REGULATION OF LEUKOCYTE PROLIFERATION 4 206 0.0004457 0.005039
412 POSITIVE REGULATION OF PROTEIN DEACETYLATION 2 18 0.0004473 0.005039
413 UTERUS DEVELOPMENT 2 18 0.0004473 0.005039
414 POSITIVE REGULATION OF DNA REPLICATION 3 86 0.0004548 0.005112
415 REGULATION OF CATION TRANSMEMBRANE TRANSPORT 4 208 0.0004622 0.005182
416 TISSUE REMODELING 3 87 0.0004705 0.005263
417 MEIOSIS I 3 88 0.0004866 0.005403
418 LEUKOCYTE PROLIFERATION 3 88 0.0004866 0.005403
419 OVULATION CYCLE PROCESS 3 88 0.0004866 0.005403
420 B CELL DIFFERENTIATION 3 89 0.0005029 0.005572
421 REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION 4 213 0.0005055 0.005587
422 REGULATION OF CELL MATRIX ADHESION 3 90 0.0005196 0.00573
423 GAMETE GENERATION 6 595 0.0005259 0.005785
424 POSITIVE REGULATION OF HOMEOSTATIC PROCESS 4 216 0.0005328 0.005847
425 REGULATION OF PROTEIN SECRETION 5 389 0.0005447 0.005963
426 CELLULAR RESPONSE TO STEROID HORMONE STIMULUS 4 218 0.0005516 0.006025
427 POSITIVE REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS 2 20 0.0005542 0.006039
428 DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION 6 602 0.0005594 0.006081
429 REGULATION OF PROTEIN STABILITY 4 221 0.0005807 0.006298
430 NEGATIVE REGULATION OF HYDROLASE ACTIVITY 5 397 0.0005973 0.006464
431 ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 3 95 0.0006086 0.00657
432 REGULATION OF PROTEIN IMPORT INTO NUCLEUS TRANSLOCATION 2 21 0.0006119 0.00659
433 MORPHOGENESIS OF AN EPITHELIUM 5 400 0.000618 0.006641
434 GLAND MORPHOGENESIS 3 97 0.0006467 0.006934
435 HEMATOPOIETIC PROGENITOR CELL DIFFERENTIATION 3 98 0.0006664 0.007128
436 REGULATION OF HAIR CYCLE 2 22 0.0006723 0.007142
437 ENDOCARDIAL CUSHION MORPHOGENESIS 2 22 0.0006723 0.007142
438 SOMATIC STEM CELL DIVISION 2 22 0.0006723 0.007142
439 REGULATION OF NEURON PROJECTION DEVELOPMENT 5 408 0.0006759 0.007164
440 NEURON DIFFERENTIATION 7 874 0.0006834 0.007227
441 EXTRINSIC APOPTOTIC SIGNALING PATHWAY 3 99 0.0006864 0.007242
442 REGULATION OF LEUKOCYTE DIFFERENTIATION 4 232 0.0006965 0.007333
443 REGULATION OF CELL ADHESION 6 629 0.0007043 0.007398
444 MODIFICATION OF MORPHOLOGY OR PHYSIOLOGY OF OTHER ORGANISM 3 100 0.0007067 0.007406
445 REGULATION OF PRODUCTION OF MOLECULAR MEDIATOR OF IMMUNE RESPONSE 3 101 0.0007275 0.007607
446 RESPONSE TO INCREASED OXYGEN LEVELS 2 23 0.0007355 0.007639
447 REGULATION OF OSTEOBLAST PROLIFERATION 2 23 0.0007355 0.007639
448 RESPONSE TO HYPEROXIA 2 23 0.0007355 0.007639
449 NEGATIVE REGULATION OF IMMUNE EFFECTOR PROCESS 3 102 0.0007486 0.007758
450 MULTI ORGANISM REPRODUCTIVE PROCESS 7 891 0.0007659 0.00792
451 REGULATION OF HISTONE DEACETYLATION 2 24 0.0008015 0.008197
452 POSITIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS 2 24 0.0008015 0.008197
453 POSITIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY 2 24 0.0008015 0.008197
454 CARDIAC EPITHELIAL TO MESENCHYMAL TRANSITION 2 24 0.0008015 0.008197
455 REGULATION OF EXECUTION PHASE OF APOPTOSIS 2 24 0.0008015 0.008197
456 CELLULAR COMPONENT MORPHOGENESIS 7 900 0.0008127 0.008292
457 ODONTOGENESIS 3 105 0.0008144 0.008292
458 REGULATION OF FAT CELL DIFFERENTIATION 3 106 0.0008372 0.008505
459 PLATELET DEGRANULATION 3 107 0.0008603 0.008721
460 LENS FIBER CELL DIFFERENTIATION 2 25 0.0008703 0.008746
461 CELLULAR RESPONSE TO TOXIC SUBSTANCE 2 25 0.0008703 0.008746
462 EPITHELIAL CELL APOPTOTIC PROCESS 2 25 0.0008703 0.008746
463 HISTONE PHOSPHORYLATION 2 25 0.0008703 0.008746
464 REGULATION OF MAPK CASCADE 6 660 0.0009051 0.009077
465 RESPONSE TO HYDROGEN PEROXIDE 3 109 0.0009077 0.009083
466 INTERSPECIES INTERACTION BETWEEN ORGANISMS 6 662 0.0009195 0.009161
467 SYMBIOSIS ENCOMPASSING MUTUALISM THROUGH PARASITISM 6 662 0.0009195 0.009161
468 RESPONSE TO CORTICOSTERONE 2 26 0.0009417 0.009363
469 ZYMOGEN ACTIVATION 3 112 0.000982 0.009742
470 PROTEIN COMPLEX SUBUNIT ORGANIZATION 9 1527 0.0009846 0.009748
471 OVULATION CYCLE 3 113 0.001008 0.009954
472 NEGATIVE REGULATION OF FIBROBLAST PROLIFERATION 2 27 0.001016 0.009973
473 POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER INVOLVED IN CELLULAR RESPONSE TO CHEMICAL STIMULUS 2 27 0.001016 0.009973
474 CELLULAR RESPONSE TO DEXAMETHASONE STIMULUS 2 27 0.001016 0.009973
NumGOOverlapSizeP ValueAdj. P Value
1 CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY 5 12 9.562e-12 2.961e-09
2 CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE REGULATOR ACTIVITY 6 28 6.699e-12 2.961e-09
3 ENZYME BINDING 19 1737 6.527e-12 2.961e-09
4 KINASE BINDING 12 606 2.372e-10 4.407e-08
5 PROTEIN COMPLEX BINDING 14 935 2.003e-10 4.407e-08
6 MACROMOLECULAR COMPLEX BINDING 16 1399 3.433e-10 5.315e-08
7 PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY 5 30 1.682e-09 2.233e-07
8 CORE PROMOTER BINDING 7 152 7.171e-09 8.327e-07
9 TRANSCRIPTION FACTOR BINDING 10 524 1.426e-08 1.471e-06
10 RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING 6 104 2.454e-08 2.28e-06
11 KINASE REGULATOR ACTIVITY 7 186 2.9e-08 2.449e-06
12 PROTEIN HETERODIMERIZATION ACTIVITY 9 468 8.011e-08 6.202e-06
13 PROTEIN KINASE ACTIVITY 10 640 9.35e-08 6.681e-06
14 CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 4 34 3.51e-07 2.329e-05
15 KINASE INHIBITOR ACTIVITY 5 89 4.551e-07 2.819e-05
16 REGULATORY REGION NUCLEIC ACID BINDING 10 818 8.974e-07 5.211e-05
17 KINASE ACTIVITY 10 842 1.167e-06 6.377e-05
18 TRANSFORMING GROWTH FACTOR BETA RECEPTOR BINDING 4 50 1.709e-06 8.82e-05
19 PROTEIN DIMERIZATION ACTIVITY 11 1149 2.492e-06 0.0001219
20 CYCLIN BINDING 3 19 4.667e-06 0.0002168
21 TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS 10 992 5.082e-06 0.0002248
22 CHROMATIN BINDING 7 435 8.713e-06 0.0003679
23 NF KAPPAB BINDING 3 30 1.93e-05 0.0007794
24 RNA POLYMERASE II ACTIVATING TRANSCRIPTION FACTOR BINDING 3 36 3.369e-05 0.001304
25 MOLECULAR FUNCTION REGULATOR 10 1353 7.47e-05 0.002776
26 UBIQUITIN LIKE PROTEIN LIGASE BINDING 5 264 9.059e-05 0.003237
27 PROTEIN SERINE THREONINE KINASE ACTIVITY 6 445 0.0001101 0.00379
28 ACTIVATING TRANSCRIPTION FACTOR BINDING 3 57 0.0001346 0.004467
29 NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY 9 1199 0.0001658 0.00531
30 TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING 5 315 0.0002068 0.006198
31 ENZYME REGULATOR ACTIVITY 8 959 0.0002009 0.006198
32 P53 BINDING 3 67 0.0002178 0.006323
33 RECEPTOR SIGNALING PROTEIN ACTIVITY 4 172 0.0002246 0.006323
34 SMAD BINDING 3 72 0.0002695 0.006956
35 GLUCOCORTICOID RECEPTOR BINDING 2 14 0.0002672 0.006956
36 LIGASE REGULATOR ACTIVITY 2 14 0.0002672 0.006956
37 CHROMATIN DNA BINDING 3 80 0.0003678 0.009235
38 STEROID HORMONE RECEPTOR BINDING 3 81 0.0003815 0.009326
NumGOOverlapSizeP ValueAdj. P Value
1 CYCLIN DEPENDENT PROTEIN KINASE HOLOENZYME COMPLEX 7 31 6.768e-14 3.952e-11
2 CHROMOSOME 14 880 9.01e-11 2.611e-08
3 PROTEIN KINASE COMPLEX 7 90 1.789e-10 2.611e-08
4 CHROMATIN 11 441 1.371e-10 2.611e-08
5 TRANSFERASE COMPLEX 12 703 1.287e-09 1.503e-07
6 TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS 8 237 6.171e-09 6.006e-07
7 TRANSCRIPTION FACTOR COMPLEX 8 298 3.671e-08 3.062e-06
8 CATALYTIC COMPLEX 12 1038 9.856e-08 7.195e-06
9 RNA POLYMERASE II TRANSCRIPTION FACTOR COMPLEX 4 101 2.844e-05 0.00167
10 NUCLEAR CHROMOSOME 7 523 2.86e-05 0.00167
11 MICROTUBULE CYTOSKELETON 9 1068 6.834e-05 0.003392
12 NUCLEAR TRANSCRIPTION FACTOR COMPLEX 4 127 6.971e-05 0.003392
13 PLATELET ALPHA GRANULE LUMEN 3 55 0.000121 0.005436
14 NUCLEAR CHROMATIN 5 291 0.000143 0.005966
15 CHROMOSOMAL REGION 5 330 0.0002565 0.009986

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 Cell_cycle_hsa04110 35 124 2.736e-80 1.423e-78
2 Cellular_senescence_hsa04218 20 160 9.905e-34 2.575e-32
3 FoxO_signaling_pathway_hsa04068 14 132 3.023e-22 5.241e-21
4 p53_signaling_pathway_hsa04115 11 68 1.174e-19 1.526e-18
5 Hippo_signaling_pathway_hsa04390 11 154 1.398e-15 1.454e-14
6 PI3K_Akt_signaling_pathway_hsa04151 11 352 1.229e-11 1.065e-10
7 TGF_beta_signaling_pathway_hsa04350 7 84 1.092e-10 8.114e-10
8 Wnt_signaling_pathway_hsa04310 8 146 1.324e-10 8.609e-10
9 Oocyte_meiosis_hsa04114 6 124 7.045e-08 4.071e-07
10 Jak_STAT_signaling_pathway_hsa04630 6 162 3.44e-07 1.789e-06
11 MAPK_signaling_pathway_hsa04010 7 295 6.677e-07 3.157e-06
12 ErbB_signaling_pathway_hsa04012 4 85 1.439e-05 6.234e-05
13 Adherens_junction_hsa04520 3 72 0.0002695 0.001078
14 HIF_1_signaling_pathway_hsa04066 3 100 0.0007067 0.002625
15 Apelin_signaling_pathway_hsa04371 3 137 0.001753 0.005589
16 Apoptosis_hsa04210 3 138 0.00179 0.005589
17 Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 3 139 0.001827 0.005589
18 Hedgehog_signaling_pathway_hsa04340 2 47 0.003061 0.008732
19 Notch_signaling_pathway_hsa04330 2 48 0.003191 0.008732
20 Focal_adhesion_hsa04510 3 199 0.005024 0.01306
21 Mitophagy_animal_hsa04137 2 65 0.005775 0.0143
22 Cytokine_cytokine_receptor_interaction_hsa04060 3 270 0.01158 0.02737
23 AMPK_signaling_pathway_hsa04152 2 121 0.01896 0.04287

lncRNA-mediated sponge

(Download full result)

Num lncRNA miRNAs           miRNAs count     Gene Sponge regulatory network lncRNA log2FC lncRNA pvalue Gene log2FC Gene pvalue lncRNA-gene Pearson correlation
1

RP11-166D19.1

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-335-5p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p;hsa-miR-96-5p 18 CCND2 Sponge network -3.855 0 -2.427 0 0.629
2

MAGI2-AS3

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-335-5p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p 16 CCND2 Sponge network -2.414 0 -2.427 0 0.545
3

MIR143HG

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-335-5p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p 17 CCND2 Sponge network -4.237 0 -2.427 0 0.544
4 RP11-284N8.3 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-96-5p 14 CCND2 Sponge network -1.414 0.007 -2.427 0 0.514
5

C20orf166-AS1

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p 13 CCND2 Sponge network -6.333 0 -2.427 0 0.513
6

LINC00702

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-877-5p;hsa-miR-96-5p 16 CCND2 Sponge network -2.704 0 -2.427 0 0.509
7

HAND2-AS1

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-423-5p 14 CCND2 Sponge network -5.605 0 -2.427 0 0.497
8

RP11-175K6.1

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-96-5p 13 CCND2 Sponge network -2.386 0 -2.427 0 0.477
9 RP11-325F22.2 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-877-5p;hsa-miR-96-5p 12 CCND2 Sponge network -1.801 0.01297 -2.427 0 0.466
10

GAS6-AS2

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p 12 CCND2 Sponge network -2.655 0 -2.427 0 0.458
11

VIM-AS1

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a 10 CCND2 Sponge network -1.424 0.00627 -2.427 0 0.455
12 LINC00861 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-378a-3p;hsa-miR-877-5p;hsa-miR-96-5p 12 CCND2 Sponge network -1.254 0.02528 -2.427 0 0.446
13 AC093627.8 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-324-3p 10 CCND2 Sponge network -5.744 0 -2.427 0 0.445
14

ADAMTS9-AS1

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-335-5p;hsa-miR-877-5p;hsa-miR-96-5p 15 CCND2 Sponge network -7.614 0 -2.427 0 0.443
15

DNM3OS

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-378a-3p;hsa-miR-96-5p 14 CCND2 Sponge network -2.298 1.0E-5 -2.427 0 0.44
16

RP11-867G23.10

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-378a-3p;hsa-miR-423-5p 11 CCND2 Sponge network -5.684 0 -2.427 0 0.437
17 AP001055.6 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-423-5p 11 CCND2 Sponge network -1.091 0.00522 -2.427 0 0.434
18

RP11-426C22.5

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-423-5p 13 CCND2 Sponge network -0.559 0.08048 -2.427 0 0.425
19 PCED1B-AS1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-877-5p;hsa-miR-96-5p 11 CCND2 Sponge network -0.575 0.17488 -2.427 0 0.418
20 LINC00092 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-423-5p 11 CCND2 Sponge network -3.407 1.0E-5 -2.427 0 0.417
21 C4A-AS1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-423-5p;hsa-miR-877-5p;hsa-miR-96-5p 13 CCND2 Sponge network -1.76 0.00265 -2.427 0 0.416
22 AC011526.1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-320a;hsa-miR-96-5p 10 CCND2 Sponge network -1.209 1.0E-5 -2.427 0 0.413
23

BZRAP1-AS1

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-335-5p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p 16 CCND2 Sponge network -2.343 0 -2.427 0 0.412
24

NR2F1-AS1

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p 16 CCND2 Sponge network -1.881 0 -2.427 0 0.411
25 LINC00996 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-335-5p 11 CCND2 Sponge network -1.208 0.03775 -2.427 0 0.406
26

RP11-753H16.3

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-320a;hsa-miR-335-5p 10 CCND2 Sponge network -5.702 0 -2.427 0 0.402
27 RP11-20J15.3 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-877-5p 12 CCND2 Sponge network -5.104 8.0E-5 -2.427 0 0.394
28

NR2F1-AS1

 hsa-miR-103a-3p;hsa-miR-107;hsa-miR-141-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-191-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-34a-5p;hsa-miR-501-3p 11 CDK6 Sponge network -1.881 0 -0.774 0.06479 0.393
29

TBX5-AS1

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-877-5p 14 CCND2 Sponge network -2.557 2.0E-5 -2.427 0 0.387
30 RP11-554A11.4 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-423-5p 11 CCND2 Sponge network -3.989 0 -2.427 0 0.379
31 RP11-693J15.4 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a 12 CCND2 Sponge network -3.319 0.00281 -2.427 0 0.375
32

AC020571.3

 hsa-let-7a-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-877-5p;hsa-miR-96-5p 11 CCND2 Sponge network -0.862 0.18422 -2.427 0 0.371
33 RP11-180N14.1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-96-5p 12 CCND2 Sponge network -4.46 0 -2.427 0 0.371
34

MEG3

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-96-5p 16 CCND2 Sponge network -2.367 0 -2.427 0 0.37
35 RP11-426C22.4 hsa-let-7a-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p 10 CCND2 Sponge network -0.045 0.93351 -2.427 0 0.367
36

LINC00883

 hsa-miR-103a-3p;hsa-miR-107;hsa-miR-141-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-191-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-34a-5p;hsa-miR-501-3p 10 CDK6 Sponge network -0.614 0.0511 -0.774 0.06479 0.364
37

LINC00702

 hsa-miR-103a-3p;hsa-miR-107;hsa-miR-141-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-191-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-34a-5p;hsa-miR-501-3p 11 CDK6 Sponge network -2.704 0 -0.774 0.06479 0.364
38

AF131217.1

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-335-5p;hsa-miR-423-5p;hsa-miR-877-5p;hsa-miR-96-5p 15 CCND2 Sponge network -5.31 0 -2.427 0 0.363
39 RP4-647J21.1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-378a-3p;hsa-miR-423-5p 11 CCND2 Sponge network -0.501 0.33476 -2.427 0 0.362
40 RP11-367G6.3 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-877-5p 10 CCND2 Sponge network -1.318 0.14472 -2.427 0 0.36
41 RP1-151F17.2 hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-335-5p;hsa-miR-877-5p;hsa-miR-96-5p 10 CCND2 Sponge network -1.606 0 -2.427 0 0.36
42

RP11-356J5.12

 hsa-miR-103a-3p;hsa-miR-107;hsa-miR-141-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-191-5p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-501-3p 10 CDK6 Sponge network -2.015 0 -0.774 0.06479 0.358
43 RP11-81H14.2 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-96-5p 13 CCND2 Sponge network -2.322 0.00014 -2.427 0 0.353
44

PDZRN3-AS1

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a 12 CCND2 Sponge network -5.049 1.0E-5 -2.427 0 0.353
45

RP11-887P2.5

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p 10 CCND2 Sponge network -6.751 0 -2.427 0 0.352
46

FENDRR

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-423-5p;hsa-miR-96-5p 15 CCND2 Sponge network -4.793 0 -2.427 0 0.35
47

ACTA2-AS1

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-96-5p 14 CCND2 Sponge network -3.838 0 -2.427 0 0.348
48 RP11-161M6.2 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-423-5p;hsa-miR-96-5p 13 CCND2 Sponge network -1.332 0.00015 -2.427 0 0.346
49 AC010226.4 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-96-5p 10 CCND2 Sponge network -1.506 0 -2.427 0 0.344
50 LINC00565 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p 11 CCND2 Sponge network -1.493 0.05998 -2.427 0 0.342
51

MIR497HG

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p;hsa-miR-96-5p 16 CCND2 Sponge network -3.802 0 -2.427 0 0.341
52

LINC00473

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-423-5p;hsa-miR-877-5p 13 CCND2 Sponge network -5.53 0 -2.427 0 0.337
53 CTC-378H22.2 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-324-3p;hsa-miR-423-5p;hsa-miR-877-5p 11 CCND2 Sponge network -1.776 0.01283 -2.427 0 0.337
54 RP11-1024P17.1 hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a 10 CCND2 Sponge network -1.552 0 -2.427 0 0.336
55

LINC00163

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p 10 CCND2 Sponge network -4.312 0.00014 -2.427 0 0.333
56

RP11-326C3.11

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-877-5p 12 CCND2 Sponge network -1.196 3.0E-5 -2.427 0 0.324
57

AC002480.3

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-378a-3p;hsa-miR-423-5p 12 CCND2 Sponge network -1.522 0.03484 -2.427 0 0.322
58

TP73-AS1

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-96-5p 16 CCND2 Sponge network -1.97 0 -2.427 0 0.321
59

RP11-456K23.1

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-877-5p 13 CCND2 Sponge network -1.962 1.0E-5 -2.427 0 0.317
60 AC002480.5 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-378a-3p 10 CCND2 Sponge network -2.128 0.02032 -2.427 0 0.312
61

RP11-805I24.3

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p 13 CCND2 Sponge network -5.815 0 -2.427 0 0.312
62

RP11-356J5.12

 hsa-let-7a-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-335-5p;hsa-miR-423-5p 14 CCND2 Sponge network -2.015 0 -2.427 0 0.31
63

LINC00327

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-96-5p 11 CCND2 Sponge network -1.951 0.01135 -2.427 0 0.306
64

BVES-AS1

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-320a;hsa-miR-378a-3p;hsa-miR-877-5p 10 CCND2 Sponge network -4.161 1.0E-5 -2.427 0 0.303
65

RP11-401P9.4

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-877-5p 13 CCND2 Sponge network -2.738 0 -2.427 0 0.299
66 RP11-403B2.7 hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-423-5p 10 CCND2 Sponge network -2.507 0.00687 -2.427 0 0.299
67 RP11-25K19.1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p 10 CCND2 Sponge network -1.478 0.00829 -2.427 0 0.298
68 RP11-1008C21.2 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p 10 CCND2 Sponge network -0.999 0.0012 -2.427 0 0.294
69

LINC00883

 hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p 11 CCND2 Sponge network -0.614 0.0511 -2.427 0 0.286
70 GATA6-AS1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p 12 CCND2 Sponge network -3.855 0 -2.427 0 0.282
71 MIR22HG hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-877-5p 11 CCND2 Sponge network -1.994 0 -2.427 0 0.281
72 CTD-2013N24.2 hsa-let-7a-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p 11 CCND2 Sponge network -1.002 1.0E-5 -2.427 0 0.279
73 DIO3OS hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p;hsa-miR-877-5p 15 CCND2 Sponge network -3.619 0 -2.427 0 0.278
74 RP11-359E10.1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-423-5p 11 CCND2 Sponge network -1.216 0.0438 -2.427 0 0.276
75 RP11-13K12.5 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-423-5p;hsa-miR-877-5p 12 CCND2 Sponge network -4.086 0 -2.427 0 0.275
76 MEG9 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-378a-3p 11 CCND2 Sponge network -3.37 3.0E-5 -2.427 0 0.273
77

RP11-536K7.3

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-877-5p 10 CCND2 Sponge network -0.673 0.17143 -2.427 0 0.272
78 RP11-389G6.3 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-378a-3p;hsa-miR-423-5p 14 CCND2 Sponge network -7.573 0 -2.427 0 0.272
79 RP4-639F20.1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-96-5p 12 CCND2 Sponge network -1.492 1.0E-5 -2.427 0 0.269
80 AC016747.3 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p 12 CCND2 Sponge network 0.026 0.94846 -2.427 0 0.267
81 HCG22 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-423-5p;hsa-miR-96-5p 12 CCND2 Sponge network -2.084 0.04175 -2.427 0 0.262
82 CTD-2554C21.3 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p 12 CCND2 Sponge network -2.359 0.00283 -2.427 0 0.257
83

LINC00982

 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-324-3p;hsa-miR-378a-3p;hsa-miR-423-5p 13 CCND2 Sponge network -3.353 3.0E-5 -2.427 0 0.254
84

FLG-AS1

 hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-301a-3p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-335-5p;hsa-miR-378a-3p;hsa-miR-877-5p 14 CCND2 Sponge network -1.812 0.00363 -2.427 0 0.253
85 RASSF8-AS1 hsa-let-7a-5p;hsa-let-7b-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-182-5p;hsa-miR-320a;hsa-miR-324-3p;hsa-miR-378a-3p 10 CCND2 Sponge network -0.877 0.00508 -2.427 0 0.253

Quest ID: 835ba7bc2c20705575380770eda67924